BioNTech appointed Guido Oelkers to its Management Board as Chief Executive Officer, succeeding Uğur Şahin, with Oelkers expected to take office by February 1, 2027, at the latest.
Healthcare & Life Sciences · Germany
Previously: BioNTech said it was advancing a lung-cancer development programme with more than 16 ongoing clinical trials, including five Phase 3 trials and two novel-novel combination trials.
Read maintained: 2026-10-26